Anti-Human CD3 Recombinant Antibody (Teplizumab) (CAT#: TAB-159)

Figure 1 Flow cytometry also demonstrates over-expression of T cell genes in rituximab-vs. placebo-treated subjects.

A Correlation of modular gene expression with cell subset levels determined by flow cytometry. Shown is a heatmap representation of the correlation between modular gene expression measured by RNA-seq vs. the percentages of cell subsets determined by flow cytometry. Gene expression was calculated as median log2 expression values in reads per million (RPM) + 1 for all genes in the indicated module. Cell subsets were determined by antibody staining and were expressed as percentages of total lymphocytes. The magnitude of Pearson's correlation coefficients (r) are represented by color intensity; Red, positive correlation; Blue, negative correlation. This plot was derived from 27 rituximab-treated subjects tested at week 26. b CD3+ and CD4+, but not CD8+ T cell subsets were transiently overexpressed in rituximab-treated subjects. Percentages of the indicated cell subsets for all subjects at all visits were normalized by z-scores ((value-mean of values)/SD of values). Shown are the z-score normalized mean percentages of the indicated cell subsets determined by flow cytometry vs. time of visit. There were 30–35 rituximab- vs. 14–17 placebo-treated subjects tested at weeks 0–104 for each marker; and 25, 4, and 2 rituximab- vs. 12, 2, and 1 placebo-treated subjects at weeks 128–176.

Linsley, P. S., Greenbaum, C. J., Rosasco, M., Presnell, S., Herold, K. C., & Dufort, M. J. (2018). Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes. Genes & Immunity, 1.

Figure 2 Schematic representation of the humanization strategy for CD3E, CD3D, and CD3G.

Representative results of RT-PCR analysis for mouse Cd3 edg or human CD3 EDG expression in the blood cells.

Ueda, O. , Wada, N. A. , Kinoshita, Y. , Hino, H. , Kakefuda, M. , & Ito, T. , et al. (2018). Corrigendum: entire cd3ε, δ, and γ humanized mouse to evaluate human cd3–mediated therapeutics. Scientific Reports, 8, 46960.

Figure 1 Anti-Human CD3 Antibody (TAB-159) in ELISA

ELISA analysis of TAB-159 was performed by coating with recombinant human CD3e protein (His Tag). Then blocked with BSA and incubated with TAB-159. The HRP-conjugated goat anti-human IgG as a secondary antibody (1:5000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 2 Anti-Human CD3 Antibody (TAB-159) in FC

Flow cytometry analysis of Jurkat cells with purified antibody TAB-159 (Lot#CB2101Y13). Cells were blocked with Human TruStain FcXTM and washed with 0.5% BSA-PBS. An FITC-conjugated goat anti-human IgG secondary antibody was added.
PC: Positive Control, Blue (Biolegend, 317306)
Lot#CB2101Y13: CB2101Y13 batch, Blue (TAB-159)